Ibio Inc (NYSEMKT:IBIO) Signs Caliber Biotherapeutics To Assist With Development of IBIO-CFB03

Ibio Inc (NYSEMKT:IBIO) has recently reached an agreement with Caliber Biotherapeutics LLC, to assist in the clinical development of IBIO-CFB03. The treatment would be the first proprietary anti-fibrosis product. The materials produced by Caliber for the treatment would be the ones used for initial clinical trials and toxicology studies. IBIO is the only company licensed […]

Ibio Inc (NYSEMKT:IBIO) Loses Its Investor Base, As All Eyes Are On ZMapp

Boston, MA 10/16/2014 (wallstreetpr) – Ibio Inc (NYSEMKT:IBIO) tumbled down by 3.57% yesterday, shrinking to share values of $1.35 per share, soon after Ebola fears astounded investors. The condition of deterioration began soon after the World Health Organization came down heavily against all key pharmaceutical companies with a report! The WHO report speaks volumes about […]

Ebola Fears: Drug And Suit Makers Up In The Market

Boston, MA 10/13/2014 (wallstreetpr) – The Ebola menace is slowly finding its way in the U.S. after a nurse who cared for an Ebola patient was also diagnosed with the virus. Companies developing cures for the diseases lead by Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) have been on an upward swing. Focus […]

Stocks To Watch: Ibio Inc (NYSEMKT:IBIO); Ardelyx Inc (NASDAQ:ARDX); Ambit Biosciences Corp (NASDAQ:AMBI)

Boston, MA 10/07/2014 (wallstreetpr) – The stock of biotechnology firm Ibio Inc (NYSEMKT:IBIO) touched new highs yesterday at the stock market. This was on the back of continued investor interest in the stock; post last week’s announcement last week that it has filed its Annual Report for FY14 to Securities and Exchange Commission on 29th […]